Alembic Pharmaceuticals Limited has announced its consolidated financial results for the second quarter ended 30 September 2025, demonstrating robust growth across key business segments. The Vadodara-based pharmaceutical company recorded strong performance in both domestic and international markets.
Revenue from operations increased by 16% YoY to ₹1,910 crore during the quarter. The company's EBITDA grew by 26% to ₹325 crore, maintaining an EBITDA margin of 17% of revenue.
Reported Profit After Tax stood at ₹185 crore, marking a 20% year-on-year increase. The pre-R&D EBITDA margin reached 26%, whilst R&D investment was maintained at around 10% of revenue.
The India Branded Business segment delivered 5% year-on-year growth, reaching ₹639 crore in revenue for the quarter. Gynaecology, Ophthalmology and Animal healthcare segments demonstrated accelerating performance.
The company successfully introduced 2 new products during the quarter, whilst the Cough and Cold segments grew in line with market performance.
Read More: Gland Pharma Reports ₹184 Crore Net Profit in Q2 FY26; Revenue Up 5.8%!
The US Generics business grew by 21% to ₹566 crore for the quarter, with 3 new launches in the US market. Ex-US International Generics segment registered an impressive 31% growth to ₹392 crore. The company received 6 ANDA approvals during the quarter, taking cumulative ANDA approvals to 226. During this period, Alembic completed the acquisition of Utility Therapeutics, providing entry into branded drugs in the US market.
The API (Active Pharmaceutical Ingredients) business segment grew by 15% to ₹261 crore for the quarter. For the half-year FY26, the API business recorded revenue of ₹575 crore compared to ₹532 crore in the corresponding period last year.
On November 4, 2025, Alembic Pharmaceuticals share price opened at ₹929.95 on NSE, above the previous close of ₹924.20. During the day, it surged to ₹998.00 and dipped to ₹927.90. The stock is trading at ₹989.00 as of 2:48 PM. The stock registered a significant gain of 7.01%.
Over the past week, it has moved up by 9.79%, over the past month, it has moved up by 9.12%, and over the past 3 months, it has moved up by 2.25%.
Alembic Pharmaceuticals' Q2 FY26 results reflect continued momentum across core businesses with 16% revenue growth and 20% PAT increase. The company's focus on complex and high-value areas such as injectables, peptides, oral solids, and drug discovery, combined with strategic acquisitions, positions it well for future growth.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Nov 4, 2025, 3:30 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN